The number of startups founded in China dropped from 51,000 in 2018 to just 1,200 in 2023, a 98% decrease. Roelof Botha attributes this collapse to unpredictable government regulations that stifle entrepreneurial risk-taking, serving as a warning for how policy could impact innovation elsewhere.
Related Insights
Contrary to the common narrative of a stifling 'crackdown,' Joe Tsai argues China's increased tech regulation established a 'new normal' that is better for business. By clarifying the 'red lines' around monopoly and privacy, the government created a more predictable environment, which is preferable to the previous era of unchecked, chaotic competition.
China's binding regulations mean companies focus safety efforts on the 31 specific risks defined by the government. This compliance-driven approach can leave them less prepared for emergent risks like CBRN or loss of control, as resources are directed toward meeting existing legal requirements rather than proactive, voluntary measures.
A surge in IPOs and M&A isn't driven by pro-business policies, but by a reduction in policy uncertainty. With a clearer, albeit more interventionist, landscape, companies have the confidence to execute major strategic plans they had previously postponed.
Unlike the U.S. government's recent strategy of backing single "champions" like Intel, China's successful industrial policy in sectors like EVs involves funding numerous competing companies. This state-fostered domestic competition is a key driver of their rapid innovation and market dominance.
China's economic structure, which funnels state-backed capital into sectors like EVs, inherently creates overinvestment and excess capacity. This distorted cost of capital leads to hyper-competitive industries, making it difficult for even successful companies to generate predictable, growing returns for shareholders.
China is poised to become the next leader in biotechnology due to a combination of structural advantages. Their regulatory environment is moving faster, they have a deep talent pool, and they can conduct clinical trials at a greater speed and volume than the U.S., giving them a significant edge.
Contrary to the Western perception of a monolithic state-run system, China fosters intense competition among its provinces. Provincial leaders are incentivized to outperform each other, leading to massive, parallel innovation in industries like EVs and solar, creating a brutally efficient ecosystem.
The immense profitability of real estate in China created a gravitational pull for capital and talent. Productive companies diverted resources to start real estate side-businesses, and entrepreneurs abandoned other sectors, resulting in a net drag on national productivity and innovation.
A cultural shift toward guaranteeing equal outcomes and shielding everyone from failure erodes economic dynamism. Entrepreneurship, the singular engine of job growth and innovation, fundamentally requires the freedom to take huge risks and accept the possibility of spectacular failure.
Despite regulatory clarity and adoption from major financial institutions like JPMorgan, the formation of new crypto companies has decreased significantly since 2021. This lull in new entrants creates a rare and massive opportunity, as the key partnerships that will define the industry for years are being decided now.
